For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ VIP
Illustration for VIP

THE PEPSRADAR ENCYCLOPEDIA

VIP

Vascular, inflammatory, and respiratory research

Research topics · Sources checked 2026-10-04

Read the studies ↓

VIP · KEY FACTS

Content updated · how dates work

What is VIP?

Vasoactive intestinal peptide participates in vascular and immune signaling. A large trial of intravenous aviptadil in COVID-19 respiratory failure did not show a significant improvement in its primary outcome.

Biological role or research focus

Vascular, inflammatory, and respiratory research.

This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.

Role reference: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Names you may encounter

Vasoactive intestinal peptide · Aviptadil

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Vasoactive intestinal peptide; aviptadil drug name
Research focus
Vascular, inflammatory, and respiratory research
Featured evidence
Human randomized trial
Source check
October 4, 2026

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Quick answers

Is VIP FDA approved?
No. No FDA-approved drug contains VIP. FDA lists it in 503A category 1: pharmacies may compound it while FDA evaluates it. Source ↗
Is VIP safe?
Not FDA-approved. Trials of synthetic VIP (aviptadil) in critical COVID-19 showed no clear benefit, and safety events were numerically more common than with placebo in the larger trial. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is VIP banned in sport?
It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

2 Human research
StudyTypePopulation / model
TESICO aviptadil trial (2023)Human randomized trial461 people with COVID-19-associated respiratory failure.
Aviptadil · earlier respiratory-failure trial (2022)Human randomized trial196 patients with critical COVID-19 respiratory failure at ten U.S. hospitals.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 2023

TESICO aviptadil trial

What did this publication test, and what did it find?

Population / model
461 people with COVID-19-associated respiratory failure.
Study design
Randomized placebo-controlled trial with a 90-day ordinal clinical outcome.
Main finding
The primary outcome was not significantly better with aviptadil: odds ratio 1.11, 95% CI 0.80–1.55, P=0.54. Mortality was also not significantly different.
Limits & context
This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Human randomized trial · 2022

Aviptadil · earlier respiratory-failure trial

How should the earlier favorable survival signal be read?

Population / model
196 patients with critical COVID-19 respiratory failure at ten U.S. hospitals.
Study design
Multicenter placebo comparison with a 60-day endpoint; participants randomized 2:1.
Main finding
The primary outcome—alive without respiratory failure—did not reach statistical significance: OR 1.6 (95% CI 0.86–3.11). A separate survival result favored aviptadil: OR 2.0 (95% CI 1.1–3.9).
How to read it
A favorable separate outcome does not turn a missed primary endpoint into a positive primary trial.
Limits & context
Secondary and subgroup signals need confirmation. Read this beside the later TESICO trial; differences in design and populations prevent selective use of favorable headlines. Neither trial establishes general wellness use of VIP.

Source: Aviptadil · earlier respiratory-failure trial · 2022 ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

15 registered studies name VIP as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 10 completed and 4 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
NCT05137795 · APR Applied Pharma Research s.a.
WithdrawnPhase 32021-12-150
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081 · QuantumLeap Healthcare Collaborative
Active, not recruitingPhase 22020-07-311500
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
NCT04843761 · National Institute of Allergy and Infectious Diseases (NIAID)
CompletedPhase 32021-04-20473
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT06729606 · National Institute of Allergy and Infectious Diseases (NIAID)
CompletedPhase 32021-04-20471
Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS
NCT04536350 · Prof. Dr. Jörg Leuppi
TerminatedPhase 22021-05-1883
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
NCT04311697 · APR Applied Pharma Research s.a.
CompletedPhase 2 / Phase 32020-05-15203
A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
NCT04844580 · Centurion Pharma
CompletedPhase 22021-03-1080
ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)
NCT04453839 · APR Applied Pharma Research s.a.
NO_LONGER_AVAILABLE

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 15 listed studies.

Search additional PubMed records ↗

Risks & interactions

Not FDA-approved. Trials of synthetic VIP (aviptadil) in critical COVID-19 showed no clear benefit, and safety events were numerically more common than with placebo in the larger trial.

Human safety data: Trials only

Data come from two trials in critically ill COVID-19 patients, a small lung study, and a combination product with phentolamine for erectile dysfunction in which 22.5% had facial flushing. Long-term safety for other uses is unknown.

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Serious risks

  • In the TESICO trial, death, serious events or organ failure by day 5 occurred in 63% with aviptadil vs 56% with placebo (not statistically significant)

Side effects reported in studies

  • facial flushing

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: TESICO: aviptadil for COVID-19 respiratory failure (2023) ↗ · Aviptadil in critical COVID-19 respiratory failure (2022) ↗ · Inhalation of VIP in pulmonary hypertension (2008) ↗ · Aviptadil and phentolamine for refractory erectile dysfunction (2025) ↗

Safety & what remains unknown

Critical-care treatment requires close monitoring. The lack of efficacy on the primary outcome must be weighed alongside treatment burdens and adverse events.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Evidence boundaries

This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Category 1 (can be compounded while FDA reviews it)
"Vasoactive Intestinal Peptide" is in 503A category 1 (under FDA evaluation; interim enforcement policy applies if its conditions are met). source
World Anti-Doping Agency (2026)
Not on the WADA Prohibited List
Not named. S0 only applies to substances with no government approval anywhere; aviptadil (VIP) is reported to be approved in some European countries in a combination product (not verified here), so whether S0 applies is uncertain. Athletes should check with their anti-doping organization. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & identity

The featured publication evaluates critical illness due to COVID-19. It does not resolve chronic gastrointestinal or immune conditions.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Seller lab-report checks and prices are available to members. Sign up free

Biology & proposed mechanism

VIP signaling has several physiological effects. Biological plausibility should be separated from the measured response to a specific preparation in a particular disease.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Questions worth asking

  • Did TESICO prove that VIP improves COVID-19 outcomes?
  • What material, population, and route were actually studied?
  • This negative comparison should remain visible. It neither proves benefit nor answers every proposed chronic use of VIP.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Video & podcast discussions: members library

Frequently asked questions

Did TESICO prove that VIP improves COVID-19 outcomes?

No. The primary comparison and the mortality comparison did not reach statistical significance.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

Does the publication verify a supplier’s product?

No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.

Source: Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. · 2023 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections